Nexalin Technology Inc Dossier
Qualitative Analysis
Business overview
Nexalin Technology, Inc. (Nasdaq: NXL) is a clinical-stage medical technology company focused on designing and developing non-invasive neurostimulation products to combat the ongoing global mental health epidemic. The company's core technology is Deep Intracranial Frequency Stimulation (DIFS™), which delivers frequency-specific electrical waveforms to stimulate deep structures of the brain associated with mood and sleep regulation. Nexalin's product pipeline includes its legacy Generation 1 (Gen-1) cranial electrotherapy stimulation (CES) device, as well as its advanced Generation 2 (Gen-2) "SYNC" system and Generation 3 (Gen-3) "HALO" Clarity headset. The Gen-3 HALO Clarity device is engineered for comfortable, physician-supervised at-home treatment utilizing a secure cloud-based telemedicine model. Currently, Nexalin is pivoting away from newly marketing its Gen-1 device in the U.S. due to regulatory reclassifications, focusing instead on international commercialization of its Gen-2 device (with approvals in markets like China and Brazil) and clinical development of its Gen-3 platform.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Planning and executing a 160-participant FDA pivotal clinical trial of the Gen-3 HALO Clarity headset targeting moderate-to-severe insomnia to support a planned De Novo FDA regulatory submission.
Expected impact: Obtaining FDA clearance for at-home, physician-supervised treatment of insomnia, opening up a multi-billion-dollar US market.
Expanding the global commercial footprint of the Gen-2 SYNC neurostimulation device in high-value international markets, including China, Brazil, Oman, and Israel.
Expected impact: Establishing early commercial revenues and clinical validation in international markets while US regulatory pathways are being cleared.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Recent Acquisitions
Acquiring the digital health platform supporting Nexalin's HALO Clarity program and Nexalin NeuroCare virtual clinic. This secures ownership of the digital infrastructure connecting the device, patient, physician, and clinical-data workflow, which is critical for the planned FDA pivotal trial and future at-home commercial deployment.
Financial impact: Fixed transaction consideration of $1.3 million structured primarily with equity-based components.
Strategic Partnerships
Provides Nexalin with continued access to GreenLight's product, engineering, quality assurance, cybersecurity, regulatory, behavioral-health, and commercial-development capabilities following the PONM acquisition.
Terms: GreenLight became a long-term strategic partner and equity holder in Nexalin.
Carmi Masha will lead all sales, marketing, clinical education, importation, registration, and distribution of Nexalin's Gen-2 Console (SYNC) neurostimulation device throughout hospitals, clinics, and private treatment centers in Israel.
Terms: Exclusive distribution rights in Israel; specific financial transfer pricing terms were not disclosed.